Capricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 Years - Capricor Therapeutics ( NASDAQ:CAPR )

7 days ago

On Friday, Capricor Therapeutics CAPR announced 3-year safety and efficacy results from its ongoing HOPE-2 open-label extension ( OLE ) study for its lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy ( DMD ) .

Ticker	Sentiment	Impact
CAPR	Somewhat Bullish	38 %